Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WONDERS2: Lepetegravir and Lenacapavir Pacfosacil vs Biktarvy in Treatment-Naive HIV-1
NCT06613685Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Oct 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of lepetegravir, lenacapavir pacfosacil in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Gilead Sciences. Started Oct 2024; status: terminated.
02
Drugs
lepetegravirlenacapavir pacfosacil
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT06613685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06613685.